Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in the September issue of the Journal of Clinical Psychiatry found once-daily VYVANSE significantly improved Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults within the first week of treatment. This study is the phase 3 pivotal trial submitted to the FDA and supported the approval in April 2008 of VYVANSE for adults with ADHD.
More: continued here